Evolus, Inc. (EOLS) is a performance beauty company with a customer-centric vision that aims to broaden the aesthetic market by providing a diverse range of services and products in the performance beauty sector. The company has its headquarters in Newport Beach, California, and maintains commercial operations in the USA, Canada, EU, and other regions.
Evolus's main product is Jeuveau™, a proprietary 900kDa purified botulinum toxin type A formulation. Jeuveau™ is structured for temporary improvement in the appearance of moderate to severe frown lines – also called glabellar lines – in adults. Botulinum toxin is renowned for its role in aesthetic medicine because of its impressive safety profile and efficacy.
As of 2019, Jeuveau™ was successfully commercialized in the USA by Evolus, marking the company's transition from a development-stage to a commercially operational company. The product, often referred to as #NEWTOX, has been endorsed by aesthetic physicians across the country and beyond for its practical viability, and it quickly became one of the leading aesthetic products in the market.
Evolus prides itself on its competitive edge gained through their expansive aesthetic portfolio and a targeted injectable strategy. This strategy acknowledges the substantial transformation in the aesthetic market landscape – one largely dominated now by self-pay consumers as against the previous third-party payers.
The performance beauty company maintains efficient operational costs by outsourcing non-core functions like manufacturing. Their strategic partnership with Daewoong Pharmaceutical Co., Ltd., South Korea, ensures consistent and quality production of their products. This seamless operation enhances Evolus's innovative business model, making it a strong contender in the global aesthetic market.
Evolus is committed to delivering innovative products that help people celebrate their own unique beauty. Rooted in science and guided by consumer’s needs, they're focused on providing healthcare practitioners the ability to offer their patients differentiated options with proven safety and effectiveness.
EOLS is publicly traded on the Nasdaq stock market and is partaking in the emerging evolution of the aesthetic market. Through its demonstrated commitment to innovation, collaboration, and customer satisfaction, Evolus, Inc. serves as a prime example of a 21st-century performance beauty company.